Compare FTCI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | RCEL |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.0M | 102.5M |
| IPO Year | 2021 | N/A |
| Metric | FTCI | RCEL |
|---|---|---|
| Price | $11.87 | $3.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $11.50 | $8.67 |
| AVG Volume (30 Days) | 87.4K | ★ 205.3K |
| Earning Date | 11-12-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $80,028,000.00 | $72,401,000.00 |
| Revenue This Year | $113.41 | $13.12 |
| Revenue Next Year | $106.67 | $27.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.53 | 20.59 |
| 52 Week Low | $2.13 | $3.22 |
| 52 Week High | $12.70 | $11.25 |
| Indicator | FTCI | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.47 | 39.76 |
| Support Level | $11.52 | $3.22 |
| Resistance Level | $12.70 | $3.61 |
| Average True Range (ATR) | 0.84 | 0.18 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 68.21 | 24.49 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.